The gut microbiome of Mexican children affected by obesity

Otoniel Maya-Lucas1, Selvasankar Murugesan1, Khemlal Nirmalkar2

  • 1Departamento de Genética y Biología Molecular, Cinvestav Unidad Zacatenco, Av IPN 2508, Ciudad de México 07360, Mexico.

Anaerobe
|October 27, 2018
PubMed

Insights

Mexican children

Area of Science:

  • Microbiome research
  • Pediatric obesity
  • Metabolic disorders

Background:

  • Obesity is a significant global health concern, particularly in Mexico where over a third of children aged 5-11 are overweight or obese.
  • Understanding the gut microbiome's role in pediatric obesity is crucial for developing effective interventions.

Purpose of the Study:

  • To investigate the gut microbiome composition and its association with metabolic factors in obese Mexican children.
  • To identify specific microbial alterations linked to obesity in this pediatric cohort.

Main Methods:

  • Metagenomic shotgun sequencing of fecal DNA from normal weight and obese Mexican children.
  • Analysis of metabolic factors and fecal short-chain fatty acids.
  • Enterotyping and comparative metabolic pathway analysis.

Main Results:

  • Obese children showed an increase in unclassified Methanobrevibacter spp. and over-representation of Megamonas spp.
  • Gut bacterial communities were characterized by enterotypes, with Prevotella spp. dominating in obese children and Ruminococcus spp. in normal weight children.
  • Depletion of Oscillospiraceae family members in obese children correlated negatively with serum cholesterol levels. Glycolysis pathways were overrepresented in normal weight children.

Conclusions:

  • Specific gut microbiome alterations are associated with obesity in Mexican children.
  • Microbiome composition can be correlated with clinical metadata, potentially aiding in stratification and identifying biomarkers.
  • Findings offer insights for the prognosis, diagnosis, and treatment of pediatric obesity through microbiome modulation.

Related Concept Videos

Obesity01:24

Obesity

The Body Mass Index (BMI) is a numerical value derived from a person's weight and height, used to categorize individuals into weight ranges. It is calculated using the formula: weight in kilograms divided by height in meters squared. Obesity is a health condition characterized by excessive accumulation of adipose tissue that poses health risks, often diagnosed with a BMI ≥ 30. This excess fat storage occurs when surplus dietary calories are converted into triglycerides and stored in...
1.3K
Drug Dosing: Obese Patients01:21

Drug Dosing: Obese Patients

In the United States, obesity is a prominent concern. It is linked to heightened mortality rates due to increased occurrences of conditions such as hypertension, atherosclerosis, coronary artery disease, and diabetes compared to nonobese individuals. A patient is classified as obese if their actual body weight surpasses the ideal or desirable body weight by 20%, based on Metropolitan Life Insurance Company data. Ideal body weights consider average weights and heights for males and females...
263
Drug Dosing: Infants and Children01:29

Drug Dosing: Infants and Children

Pediatric patient dosages diverge from adults due to disparities in body surface area, total body water, and extracellular fluid per kilogram of body weight. The dosing regimen considers the variations in pharmacokinetics and pharmacology across distinct age groups, encompassing preterm newborns, infants, young children, older children, and adolescents. Calculation of pediatric patient doses is predicated on determining body surface area, which exhibits a superior correlation with the child's...
295
Pharmacokinetics in Obese Patients: Drug Absorption and Distribution01:25

Pharmacokinetics in Obese Patients: Drug Absorption and Distribution

Obesity significantly alters the pharmacokinetic processes of drug absorption and distribution, presenting unique challenges in medical treatment. The increased fat tissue and decreased lean muscle in obese individuals can significantly affect how drugs are absorbed into the body and distributed across different tissues. This alteration can lead to variances in the effectiveness and safety of medications, necessitating adjustments in dosing or drug selection for obese patients.One notable...
282
Pharmacokinetics in Obese Patients: Drug Metabolism and Excretion01:20

Pharmacokinetics in Obese Patients: Drug Metabolism and Excretion

Drug metabolism, a critical process in the liver, involves two primary phases: Phase I reactions and Phase II conjugation. Obesity introduces significant alterations in this metabolic process, primarily due to fatty infiltration of the liver, leading to conditions such as nonalcoholic fatty liver disease (NAFLD). This condition can modify the activities of both Phase I and II enzymes, impacting how drugs are metabolized in obese patients.Phase I metabolism sees variable effects across...
184
Physiology of Enteric Nervous System and Gut Health01:05

Physiology of Enteric Nervous System and Gut Health

The gastrointestinal tract, responsible for the digestion and absorption of nutrients, is safeguarded by the intestinal barrier, which consists of secretory, physical, and immune components. At the forefront is the secretory barrier, composed of essential elements such as mucus, gut microbiota, and defense proteins. They collaborate to break down food particles, facilitate nutrient absorption, and maintain optimal gut health. These secretory components ensure the smooth functioning of the...
981